Branded and generic pharma manufacturer scaling rare disease commercialization
ANI Pharmaceuticals manufactures and markets branded generics and rare disease products, with a public markets listing (Nasdaq: ANIP). The hiring profile reveals a sales-heavy push: 42 of 77 active roles are sales-focused, concentrated at mid and senior levels, supporting multiple concurrent commercial initiatives including Cortrophin Gel market development and physician education campaigns. Their tech stack emphasizes manufacturing oversight (MES, LIMS, SCADA, DCS) and analytics (Power BI, Tableau) — typical of regulated pharma operations — with recent Azure and Kubernetes adoption suggesting infrastructure modernization.
Notable leadership hires: Business Director, Area Business Director, Clinical Operations Director
ANI Pharmaceuticals is a diversified biopharmaceutical company developing, manufacturing, and marketing prescription products across branded established brands, generics, and rare disease segments. Headquartered in Princeton, New Jersey, the company operates U.S. manufacturing facilities for solid dose, liquid dose, hormone, and controlled substance formulations, as well as contract manufacturing and packaging services. The commercial focus is anchored on scaling Cortrophin Gel, a rare disease lead asset, while strengthening the generic product portfolio and expanding physician and patient awareness through direct sales and clinical education efforts.
ANI uses manufacturing systems (MES, LIMS, SCADA, DCS, HMI), supply chain visibility (Tracelink), business intelligence (Power BI, Tableau), cloud infrastructure (Azure, Kubernetes, Docker, Terraform), and enterprise HR/finance tools (ADP Workforce Now, Concur, Microsoft Office).
ANI actively hires in the United States, India, Ireland, United Kingdom, and Canada, with notable roles in sales leadership (Business Director, Area Business Director) and clinical operations.
Other companies in the same industry, closest in size